Poster Finalists - AMR Conference 2025

Title	Institution	First name	Last name	Country
Patient-specific point-of-care system for rapid combination therapy of fungal infections-Mykopoint	Charité Universitätsmedizin Berlin	Sophie	Becke	Germany
Ultra-Fast Pathogen Identification in Sepsis Diagnosis Using an Optomechanical Sensor Assisted by Artificial Intelligence	Nanological	Blanca	Caballero	Spain
Interim Results from the Analytical Validation of Rapid Direct from Urine and Urine Isolate Microcapillary Antimicrobial Susceptibility Testing (AST)	Astratus Ltd.	Julie	Hart	United Kingdom
Same day visual bacterial identification and semi-quantitativeantibiotic sensitivity assay directly from clinical samples	Diagopreutic Pvt. Ltd.	Roshan	Naik	India
CRISPR-based diagnostics for resistance guided therapy of gonorrhea at the point-of-care	ETH Zurich	Carolina	Paganini	Switzerland
Rapid and specific detection of pathogenic bacteria using recombinant receptor binding proteins of bacteriophages	Fraunhofer Institute for Translational Medicine and Pharmacology	Leonie	Reetz	Germany
MyLabReady® for rapid and accurate point of care (POC) diagnosis of symptomatic infections and AMR guidance	LabReady Ltd	Leonard	Weisman	United Kingdom
Accelerating single-domain antibody discovery against S.aureus ClfA to combat Antimicrobial Resistance (AMR): A high-efficiency yeast surface display platform	Immunochem	Geoffrey	Holsbeek	Belgium

Pan-*Candida* monoclonal antibodies as novel immunotherapies to treat drug resistant life-threatening invasive candidiasis	University of Aberdeen	Carol	Munro	United Kingdom
Designing metabolically enhanced next-generation probiotics to eradicate multi-drug resistant bacteria from the gut	Helmholtz Centre for Infection Research	Lisa	Osbelt	Germany
Exploring the Association Between Study Characteristics and Post-Vaccine Immunogenicity for C. diff: Data-Driven Analyses of Two Vaccine Trials	Paul-Ehrlich-Institute	Igor	Stojkov	Germany
Exploring antimicrobial activities of extremophilic bacteriophages	University of Jeddah	Abeer Mohammed	Abduljawad	Saudi Arabia
Exploring Antimicrobial Activities of Isolated Bacteriophages from Water Contaminated by House Fly (Musca domestica)	University of Jeddah	Afrah Ammar	Altalhi	Saudi Arabia
Understanding Bacterial Resistance Mechanisms: Insights from Porin Mutations in Klebsiella pneumoniae	University of Cagliari	Matteo	Ceccarelli	Italy
FibriLysins as next-generation endolysins targeting multicellular staphylococcal communities	KU Leuven	Vincent	De Maesschalck	Belgium
HY-133, a chimeric endolysin in the clinical development for nasal decolonization of Staphylococcus aureus	University Hospital Greifswald	Evgeny	Idelevich	Germany
Pseudomonas aeruginosa secondary metabolite activates lysis–lysogeny switch leads to prophage induction in Staphylococcus aureus	University of Vienna	Shubham	Joge	Austria
LysGN as a potential enzybiotics against Gram-Negative ESKAPE Pathogens	Indian Institute of Technology, Bombay	Ruqaiyah	Khan	India
Bacteriophage, or ‘phage’ products represent a powerful strategy to combat the escalating global burden of bacterial antimicrobial resistance (AMR)	Medicines and Healthcare Products Regulatory Agency	Matthew	Lamaudière	United Kingdom
AI-Driven Prediction of Phage Receptor-Binding Proteins for Phage Therapy	University of Liverpool	Hanshuo	Lu	United Kingdom

LYSG101: A Highly Potent Chimeric Bacteriophage Lysin Against Staphylococcus aureus	Precision Biotix Therapeutics	Assaf	Raz	USA
Discovery of Immune-Responsive Gene 1 (IRG1) Modulators as Potential Host-Directed Anti-infective Agents	Helmholtz Institute for Pharmaceutical Research Saarland	Gabriele	Bianchi	Germany
Discovery & Exploratory Research at the Global Antibiotic Research & Development Partnership (GARDP): Objectives and Progress	GARDP	Benjamin	Blasco	Switzerland
Combining growth inhibition assays and metabolic profiling to accelerate discovery of antibiotics with unconventional modes of action	University of Basel	Benjamin	Demarco	Switzerland
A novel class of metalloid-based antibiotic compounds	University of York	Angelo	Frei	United Kingdom
Trichloroacetimidamides: a novel class of specific antibiotics	Université Côte d'Azur	Juan	Garcia-Sanchez	France
Split inteins for generating combinatorial nonribosomal peptide libraries	Max Planck Institute for Terrestrial Microbiology	Patrick	Gonschorek	Germany
Disperazol platform-technology: the solution to the developing AMR crisis?	Disperazol Pharma ApS	Michael	Graz	Denmark
Identification, Optimization and Validation of a New Triaromatic Pleuromutilin Antibiotic Subclass	University of Southern Denmark, 5230 Odense	Christoffer	Heidtmann	Denmark
Mucus-derived glycans as a therapeutic strategy for cross-kingdom pathogens	University of Basel	Rachel	Hevey	Switzerland
Dipeptidic Phosphonates: Potent Inhibitors of Pseudomonas aeruginosa Elastase B Showing Efficacy in an in vivo Murine Keratitis Model and an ex vivo Human Cornea Assay	Helmholtz Institute for Pharmaceutical Research Saarland	Lukas	Hiller	Germany
CF-AMR Syndicate Collaborative Discovery Programme to accelerate the development of antimicrobials to treat lung infections in cystic fibrosis	MD Catapult	Lesley	Jenkinson	United Kingdom

In Vivo Activity Profiling of Biosynthetic Darobactin D22 Against Critical Gram-negative Pathogens	Helmholtz Institute for Pharmaceutical Research Saarland	Andreas	Kany	Germany
An innovative antibacterial drug discovery system and its results: lysocin E	Silk Strand Pharmaceuticals Co., Ltd.	Takeo	Kohda	Japan
Targeting the Bacterial Sliding Clamp for the Treatment of Gram-Positive Bacterial Infections	Helmholtz Institute for Pharmaceutical Research Saarland	Niklas	Krappel	Germany
Targeting the dynamic BAM–SurA holo insertase complex with novel antibiotics	University of Basel	Philippe	Lehner	Switzerland
Design, synthesis, in vitro and in vivo evaluation of unexplored trisindolines as potent anti-MRSA agents targeting cell membrane	CSIR-Indian Institute of Integrative Medicine Jammu and Kashmir	Avisek	Mahapa	India
Biotechnological methodologies for BamA Inhibitor derivatization	Justus-Liebig-University of Giessen	Michael	Marner	Germany
Preclinical development of vancomycin polycationic peptide conjugate (VN-R6C) with high antimicrobial activity *in vitro* and *in vivo*	University of Heidelberg	Eric	Mühlberg	Germany
CRS3123: A Narrow Spectrum Agent for Treatment of *C. difficile* Infection (CDI)	Crestone, Inc.	Urs	Ochsner	USA
Broadening of the antifungal pipeline by the use of polymeric nanoparticles	Leibniz Institute for Natural Product Research and Infection Biology	Thomas	Orasch	Germany
Discovery of novel oxepanoprolinamide antibiotics effective against multidrug-resistant bacteria	Kinvard Bio, Inc.	Lloyd	Payne	USA
Development of the natural product Corallopyronin A to treat filarial nematode infections and antibiotic-resistant staphylococci infections	University Hospital Bonn	Kenneth	Pfarr	Germany
Addressing AMR in Helicobacter pylori by FDA-approved drugs as novel anti-infectives	Technical University of Munich	Dietmar	Pfeiffer	Germany
Some antiretroviral therapies inhibit the growth of selected cervicovaginal microbes with potential protective role in pre-term birth	Imperial College London	Veronica	Preda	United Kingdom

The missing piece in the puzzle: APC148 – a safe, selective and efficient metallo-β-lactamase inhibitor	Adjutec Pharma AS	Pål	Rongved	Norway
Innovative Aminoglycosides: Potent, Safe, and Orally Bioavailable Antibiotics Against AMR	Palacky University in Olomouc	Kaloud	Salama	Czech Republic
MraY Enzyme: Crucial Target for Innovative Antibiotics	Palacky University in Olomouc	Kaloud	Salama	Czech Republic
Battlestar™: A Biodegradable Delivery System for Addressing AMR and Biofilm-Associated Infections Using in situ Generated Oxidative Biocides	AGA Nanotech Ltd.	Harsha	Siani	United Kingdom
Identification of mucosal glycans that regulate the acute-to-chronic infection switch in Pseudomonas aeruginosa	University of Basel	Alem	Storani	Switzerland
Semisynthetic Amides of Polyene Antibiotic Natamycin	Constructor University	Anna	Tevyashova	Germany
Small molecule antibiotic against A. baumannii without cross-resistance and potential new MoA	Helmholtz Centre for Infection Research	Alexander	Titz	Germany
Peptide-modified β-lactam antibiotics with an extended efficacy spectrum	Heidelberg University Hospital	Philipp	Uhl	Germany
Potent in vivo efficacy demonstrated for epidermicin NI01 in an MRSA wound infection model	Amprologix Ltd	Mathew	Upton	United Kingdom
Repurposing Bismuth-Based Drugs to Overcome Antibiotic Resistance in Pseudomonas aeruginosa	Omnicin Therapeutics BV	Auke	van Heel	Netherlands
Inhibiting Bacterial Biofilms to Potentiate Antibiotics and Prevent Recurrent Infections	BioTryp Therapeutics	Ash	Zarkan	United Kingdom
The antibiotic discovery accelerator (ABX); catalysing antimicrobial discovery from academia through industry into the clinic	Aston University	Jonathan	Cox	United Kingdom
Cystic fibrosis sputum media induces an overall loss of antibiotic susceptibility in Mycobacterium abscessus	Aston University	Jonathan	Cox	United Kingdom

A model to investigate anti-virulence strategies against Salmonella	University of Basel	Alaa	Alhayek	Switzerland
Poly(N-acryloyl-D-aminoalanine) shows anti-Staphylococcus aureus biofilm activity using both in vitro and in vivo models	AO Research Institute Davos	Marco	Chittò	Switzerland
RaMoA: Combination of Raman micro-spectroscopy with deep learning for rapidly predicting the Mechanism of Action of an antimicrobial and its potential novelty	Bioaster	Sophie	Dixneuf	France
Escherichia coli resistance against 'living antibiotic' Bdellovibrio bacteriovorus	University of Zurich	Simona	Huwiler	Switzerland
Relating Outer Membrane Permeability with Activity in *E. coli* by Employing Statistics-Based Machine Learning	University of Cagliari	Stefan	Milenkovic	Italy
The role of an uncharacterizedfamily of α/β-hydrolases in the antimicrobial resistance	University of Saskatchewan	Iryna	Myziuk	Canada
Unraveling the role of the Central metabolism in mediating tolerance in Uropathogenic Escherichia coli	University of Basel	Yannick	Revaz	Switzerland
Development of a Synthetic Human Urine formulation for the study of UPEC physiology and the discovery of antibiotics	University of Basel	Benjamin	Sellner	Switzerland
Benefits of group sequential design and sample size re-estimation for RCTs evaluating the prevention of ventilator-associated pneumonia: A simulation study informed by real world data	Geneva University Hospital	Holly	Jackson	Switzerland
AMROrbit Scorecard: A Dynamic Phase Space Model for Strategic Monitoring and Actionable Insights on Global AMR Trajectories in Urinary Tract Infections	Indraprastha Institute of Information Technology, Delhi	Jasmine	Kaur	India
From awareness to ac-on: can we do more to combat an-microbial resistance in heavily immunocompromised pa-ents?	Menarini Global Team	Diego	Lopez	Spain

Recommended Approaches for Integration of Population Pharmacokinetic Modelling with Precision Antibiotic Dosing in Clinical Practice	Vesynta Ltd.	Emily	Heron	United Kingdom
Preclinical murine models for studying lung infections and antimicrobial treatments of nontuberculous mycobacteria	IRCCS Ospedale San Raffaele	Nicola	Lorè	Italy
An in vivo-like lung infection model for pharmacokinetics and -dynamics studies	University of Basel	Leoni	Swart	Switzerland
A PK/PD modelling workflow for evaluating empirical antibiotic combination therapies: application to neonatal sepsis in the BARNARDS study	Leiden University	Wisse	van Os	Netherlands
DEVELOPMENT OF A MUCIN GLYCAN LIBRARY FOR STUDYING VIRULENCE ATTENUATION IN PATHOGENS	University of Basel	Carmen	Cori Calizaya	Switzerland
Medical devices with non-antibiotic antimicrobial surface coatings: A preventive approach to combat biofilm formation and bacteria dissemination	Spartha Medical	Skander	Hathroubi	France